DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
RIGL Rigel Pharmaceuticals Update Feb 2026
Rigel Pharmaceuticals [finance:Rigel Pharmaceuticals, Inc.] is a rare breed in biotech: profitable, cash-generative, and growth-oriented.
OSCR Oscar Health
oscr-aca-catalyst-report-nov24-2025.html OSCR Breaking News | Oscar Health | Merlintrader ?? ?? OSCR BREAKING CATALYST ACA SUBSIDY EXTENSION November 24, 2025 | Political Healthcare Policy Breakthrough OSCR CATALYST ACUTO ESTENSIONE SUSSIDI ACA 24 Novembre 2025 | Breakthrough Politica Healthcare Executive Summary…
ENLV Enlivex Therapeutics
Enlivex Therapeutics [finance:Enlivex Therapeutics Ltd.] announced two simultaneous catalysts on November 23-24, 2025, triggering a 74% intraday spike to $1.59: (1) positive 6-month topline data from the Allocetra Phase IIa trial demonstrating durable pain reduction, and (2) a $212M PIPE financing at $1.00/share closing November 25. The clinical data supports Phase IIb progression, but the financing creates massive shareholder dilution (~99%) and introduces governance/crypto risks requiring careful assessment.
Weekly Market Analysis Nov 24
The major US stock indices closed the week of November 22 with significant losses, despite a Friday rebound.
ALT Altimmune, Inc.
Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases.
PLX Protalix Biotherapeutics
Protalix Biotherapeutics (NASDAQ: PLX) is an Israeli biotech company specializing in plant cell-expressed recombinant proteins using its proprietary ProCellEx platform.
OTLK Outlook Therapeutics, Inc.
Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVA™), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).
Palatin Technologies Inc.
Palatin Technologies (NYSE American: PTN) is a micro-cap biotech specializing in obesity treatment through melanocortin-4 receptor (MC4R) agonists.
BCRX BioCryst Pharmaceuticals nov 21
Positive Pediatric Catalyst:
FDA approval on December 12 could represent a doubling of TAM (Total Addressable Market) by adding the completely underserved pediatric segment (zero approved oral therapies).
RGNX REGENXBIO
Currently at channel support , technically a good entry point . REGENXBIO Inc. (RGNX) is facing a landmark FDA decision on February 8, 2026 regarding approval of RGX-121 (clemidsogene lanparvovec), a one-shot AAV gene therapy for MPS II (Hunter Syndrome).
Aldeyra Therapeutics dec 16 PDUFA
Aldeyra Therapeutics (ALDX) – Comprehensive PDUFA Report ?? ?? Aldeyra Therapeutics Ticker ALDX PDUFA Date December 16, 2025 Current Price ~$5.16 Report Date November 21, 2025 ? Executive Summary Aldeyra Therapeutics (ALDX) is approaching a pivotal catalyst: a binary FDA…
NVRI Enviri Corporation
Enviri Corporation Announces Sale of Clean Earth to Veolia for $3.04 Billion and Taxable Spin-Off of Harsco Environmental and Rail Businesses ("New Enviri") to Shareholders
MNDR Mobile-health Network Solutions
Mobile-health Network Solutions (MNDR) announced a non-binding MOU on November 19, 2025, to acquire two AI-optimized data centers in Malaysia valued up to $120 million.
Top 10 Healthcare Small-Caps Stocks
Top 10 Healthcare Small-Caps Stocks Nov '25
NUVB Oncology Breakout
?? EN ?? IT ✅ NUVB — Oncology Breakout & Commercial Growth Story IBTROZI FDA Approval Success | Q3 Revenue +100% Beat | TRUST-IV Phase 3 Catalyst | $549M Cash | +111% YTD Performance Nuvation Bio — Approved PK activator…
AGIO
AGIO "From Crisis to Recovery: How Dec 7 + Jan 22 PDUFA Decisions Could Drive +80–120% Upside"
STEC E-Commerce Revolution
Intraday Move premarket gainer
KZIA
KZIA Stock Analysis: Biotech Breakthrough in Triple-Negative Breast Cancer | Kazia Therapeutics ?? EN ?? IT ⚡ KZIA — The Breakthrough Moment Immune-Complete Response (iCR) Achieved | Stage IV Metastatic TNBC | +51% Surge on iCR Announcement Kazia Therapeutics —…
⚡ “OMER — The Biotech Force Awakens”
⚡ “OMER — The Biotech Force Awakens”
Weekly report nov 17-24 2025
Weekly report nov 17-24 2025